Largest-ever Canadian clinical trial tests ‘poop pills’ to improve immunotherapy for lung cancer
For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. A clinical trial will pair immunotherapy with fecal microbiota transplantation (FMT) with the goal of safely increasing treatment effectiveness. If successful, it could provide new treatment options for people with lung cancer.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.